Clinical trials
Locally Advanced or Metastatic Non-small Cell Lung Cancer clinical trials
Below are recruiting locally advanced or metastatic non-small cell lung cancer clinical trials, each written for real people, not researchers. We’re tracking 3,522 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06000917RecruitingPhase 2
Study of combination therapy before surgery for ER+/HER2+ breast cancer
This trial tests a combination of targeted therapies and chemotherapy given before surgery for women with a specific type of breast cancer that is both ER-positive and HER2-positive. The goal is to see if this treatment can shrink tumors and improve outcomes.
Wuhan, HubeiAges 18–75 - NCT06035250Recruiting
AI predicts stomach cancer response to chemo before surgery
This study tests whether an AI tool can predict how well stomach cancer responds to chemotherapy before surgery. It uses CT scans and biopsy images taken before treatment starts to see if the AI can help guide future care.
BeijingAges 18 years+ - NCT06062927Recruiting
Genes and scans predict response to immunotherapy and targeted therapy for advanced sarcoma
This trial is testing whether a combination of two drugs—a targeted therapy (surufatinib) and an immunotherapy (envafolimab)—can help people with advanced soft tissue sarcoma that has spread or cannot be removed by surgery. Researchers will also use a person's genetic information and scans to see if they can predict who will benefit the most.
Beijing, Beijing MunicipalityAges 18–75 - NCT05777824RecruitingPhase 2
Testing treatment after head and neck cancer response to chemo-immunotherapy
This Phase 2 study looks at what treatment is best after you first receive chemotherapy plus immunotherapy, then have surgery for head and neck squamous cell cancer. It tries to use how your tumor responds (shown in lab tissue after treatment) to guide the next steps, which may improve outcomes.
Beijin, Beijing MunicipalityAges 18–75 - NCT06122493RecruitingPhase 2
Better treatment for advanced esophageal cancer
This trial tests a new treatment plan for people with advanced esophageal squamous cell carcinoma that has spread to lymph nodes but not to other organs. It aims to find the best way to treat this cancer using radiation and other therapies.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT05427383RecruitingPhase 2/Phase 3
KN026 plus chemo for HER2-positive stomach cancer after first treatment failure
This trial tests KN026 together with chemotherapy in people with HER2-positive advanced stomach (or gastro-esophageal junction) cancer that has already grown despite first-line treatment with trastuzumab plus chemotherapy. It may help by targeting HER2 while also using chemotherapy to control the cancer.
BeijingAges 18 years+ - NCT06061146RecruitingPhase 2
Tislelizumab plus chemoradiation for older esophageal cancer patients
This trial tests a combination of an immunotherapy drug (tislelizumab) with chemotherapy and radiation for older adults (70+) with advanced esophageal cancer that hasn't been treated before. The goal is to see if this approach can help control the cancer while keeping quality of life.
Tianjin, Tianjin MunicipalityAges 70–90 - NCT06197139RecruitingPhase 1
Study of a new targeted radiation therapy for advanced solid tumors
This trial tests an investigational drug called [177Lu]Lu-XT117, which delivers a small dose of radiation directly to cancer cells that have a specific protein called FAP. It is for people with advanced solid tumors who have run out of standard treatment options or cannot tolerate them.
GuangzhouAges 18 years+ - NCT06084416RecruitingPhase 1
Pill study for advanced ovarian cancer that resists chemo
This trial tests an experimental drug called sovilnesib (taken as a pill) for people with advanced ovarian, fallopian tube, or peritoneal cancer that has stopped responding to platinum chemo. The goal is to see if this drug can shrink or slow the cancer.
Birmingham, AlabamaAges 18 years+ - NCT06211647RecruitingPhase 1
177Lu XT117 for advanced solid tumors
This trial tests a new radioactive drug, [177Lu]Lu-XT117, that seeks out and delivers radiation to solid tumors that have a specific marker called FAP. It's for people whose cancer has not responded to other treatments or who have no other options.
BeijingAges 18 years+ - NCT05967910Recruiting
How stress affects immunotherapy for esophageal cancer
This study looks at whether chronic stress changes how well immunotherapy (ICI therapy) works in people with esophageal cancer. It may help doctors understand who benefits most from treatment and how stress could affect outcomes.
Changsha, HunanAges 18–75 - NCT02925234RecruitingPhase 2
Basket trial of reused cancer drugs matched to tumor markers
This trial tests cancer drugs that are already approved for other cancers, chosen based on specific changes found in your tumor. It may help people whose cancer is growing despite standard treatment (or who no longer have standard options).
AlkmaarAges 18 years+ - NCT07855926Recruiting
Perioperative drug therapy for muscle-invasive bladder cancer
This study looks at different drug treatments given around the time of surgery for muscle-invasive bladder cancer. It aims to understand how well these treatments work and may help guide future care.
MunichAges 18 years+ - NCT06268652RecruitingPhase 3
Personalized treatment guided by lab-grown tumor samples for advanced breast cancer
This trial tests whether using a personalized approach—growing your tumor cells in the lab to find the best treatment—can work better than standard treatments chosen by your doctor. It is for people with advanced breast cancer that has stopped responding to at least two previous treatments.
Guangzhou, None SelectedAges 18 years+ - NCT06223841RecruitingPhase 1/Phase 2
Testing IAP0971 for advanced solid tumors and lung cancer
This trial tests a new drug, IAP0971, in patients with advanced solid tumors or a specific type of lung cancer (non-small cell lung cancer, or NSCLC) that has high PD-L1 levels. It aims to see if the drug can help when standard treatments have stopped working or are not an option.
Beijing, Beijing MunicipalityAges 18–75 - NCT05999149RecruitingPhase 3
Famitinib plus chemo and immunotherapy before breast cancer surgery
This trial tests whether adding a targeted therapy pill (famitinib) to standard chemo plus an immunotherapy (camrelizumab) can shrink triple negative breast cancer before surgery. It may help people with earlier-stage disease who have not had certain prior treatments.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT07854600RecruitingPhase 2
Ivonescimab plus chemotherapy before surgery for bile duct cancer
This trial tests a new drug combination given before surgery to shrink bile duct cancer tumors, potentially making surgery more successful. It is for patients whose cancer is locally advanced or has spread to only a few places.
Beijing, Beijing MunicipalityAges 18–80 - NCT06101082RecruitingPhase 1
Testing anti-HER2-CAR-T cells for advanced solid tumors
This study tests a new type of cell therapy called anti-HER2-CAR-T for people with advanced HER2-positive solid tumors (like breast, stomach, or colon cancer) whose cancer has not responded to other treatments. The therapy uses your own immune cells engineered to target and kill cancer cells.
Shenyang, LiaoningAges 18–70 - NCT05116475RecruitingPhase 3
New prostate cancer trial adding darolutamide to standard treatment
This Phase 3 trial tests whether adding darolutamide to standard hormone therapy and radiation works better than standard treatment alone for newly diagnosed prostate cancer that has spread to pelvic lymph nodes. If you qualify, you may receive darolutamide or a placebo alongside long-term hormone therapy and radiation.
Chambray-lès-ToursAges 18–120 - NCT06240546RecruitingPhase 1
Study of LPM6690176 for advanced solid tumors
This trial tests a new drug called LPM6690176 for people with advanced solid tumors that have not responded to standard treatments. The goal is to see if it is safe and how it affects the body.
BeijingAges 18–75 - NCT06223256RecruitingPhase 1
NBL-028 for advanced solid tumors with CLDN6
This trial tests a new drug called NBL-028 in people with advanced solid tumors that have a specific protein (CLDN6). It is for those who have already tried standard treatments. The goal is to see how safe and effective the drug is.
Shijiazhuang, HebeiAges 18 years+ - NCT05877924RecruitingPhase 1
Early-phase study of an injected cancer treatment for advanced tumors
This Phase 1 trial tests NBL-020, an injected medicine, in adults with advanced solid cancers (and possibly some skin T-cell lymphoma) to see how it works and how safe it is. You may be considered if standard treatment has stopped working or isn’t tolerated and if you can provide recent tumor tissue for lab testing.
Guanzhou, GuangdongAges 18 years+ - NCT06343077RecruitingPhase 2
Hiltonol injection for prostate cancer on active surveillance
This trial tests a drug called Hiltonol (Poly-ICLC) given directly into the prostate tumor along with an injection under the skin. It is for men with low-risk prostate cancer who are on active surveillance, to see if the drug can slow or stop the cancer from growing.
New York, New YorkAges 18 years+ - NCT05263479RecruitingPhase 1
Study drug for advanced solid tumors that can’t be treated
This Phase 1 trial tests HS-20089 in people with advanced solid cancers that have limited standard treatment options. It focuses on safety and early signs of whether the drug can shrink tumors or control them.
Shanghai, Shanghai MunicipalityAges 18 years+
Hear when a new Locally Advanced or Metastatic Non-small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for locally advanced or metastatic non-small cell lung cancer?
- Yes. Clin2 currently lists 3,522 recruiting locally advanced or metastatic non-small cell lung cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a locally advanced or metastatic non-small cell lung cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a locally advanced or metastatic non-small cell lung cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Locally Advanced Non-Small Cell Lung Cancer
- Advanced or Metastatic Non-small Cell Lung Cancer
- Metastatic Non-squamous Non Small Cell Lung Cancer
- Advanced Non-squamous Non-small-cell Lung Cancer
- NSCLC (Advanced Non-small Cell Lung Cancer)
- Non Small Cell Lung Cancer Metastatic
- Non Small Cell Lung Cancer
- Non-squamous Non-small Cell Lung Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.